WQ3 Stock Overview
Provides genetic diagnostic solutions in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HyEnergy S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.47 |
| 52 Week High | zł0.75 |
| 52 Week Low | zł0.27 |
| Beta | 1.13 |
| 11 Month Change | -21.52% |
| 3 Month Change | -14.75% |
| 1 Year Change | -20.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| WQ3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.2% | 1.8% | 1.0% |
| 1Y | -20.7% | 6.2% | 7.7% |
Return vs Industry: WQ3 underperformed the German Life Sciences industry which returned 6.2% over the past year.
Return vs Market: WQ3 underperformed the German Market which returned 7.7% over the past year.
Price Volatility
| WQ3 volatility | |
|---|---|
| WQ3 Average Weekly Movement | 11.0% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WQ3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WQ3's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | n/a | www.inno-gene.pl |
HyEnergy S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
HyEnergy S.A. Fundamentals Summary
| WQ3 fundamental statistics | |
|---|---|
| Market cap | €23.06m |
| Earnings (TTM) | -€1.45m |
| Revenue (TTM) | €86.84k |
265.6x
P/S Ratio-15.9x
P/E RatioIs WQ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WQ3 income statement (TTM) | |
|---|---|
| Revenue | zł373.00k |
| Cost of Revenue | zł683.00k |
| Gross Profit | -zł310.00k |
| Other Expenses | zł5.92m |
| Earnings | -zł6.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -83.11% |
| Net Profit Margin | -1,668.90% |
| Debt/Equity Ratio | 1.1% |
How did WQ3 perform over the long term?
See historical performance and comparison